<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="correction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2022.1063651</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Loria</surname>
<given-names>Rossella</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1683832"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vici</surname>
<given-names>Patrizia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/517740"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Di Lisa</surname>
<given-names>Francesca Sofia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soddu</surname>
<given-names>Silvia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maugeri-Sacc&#xe0;</surname>
<given-names>Marcello</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Bon</surname>
<given-names>Giulia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">*</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1350690"/>
</contrib>
</contrib-group>    <aff id="aff1">
<sup>1</sup>
<institution>Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute</institution>, <addr-line>Rome</addr-line>, <country>Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute</institution>, <addr-line>Rome</addr-line>, <country>Italy</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Medical Oncology A, Department of Radiological, Oncological, and Anatomo-Pathological Sciences, Umberto I University Hospital, University Sapienza</institution>, <addr-line>Rome</addr-line>, <country>Italy</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute</institution>, <addr-line>Rome</addr-line>, <country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Giulia Bon, <email xlink:href="mailto:giulia.bon@ifo.it">giulia.bon@ifo.it</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>10</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>12</volume>
<elocation-id>1063651</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>10</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Loria, Vici, Di Lisa, Soddu, Maugeri-Sacc&#xe0; and Bon</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Loria, Vici, Di Lisa, Soddu, Maugeri-Sacc&#xe0; and Bon</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" xlink:href="10.3389/fonc.2022.877380" ext-link-type="doi">A Corrigendum on <article-title>Cross-resistance among sequential cancer therapeutics: An emerging issue</article-title> By Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-Sacc&#xe0; M, Bon G. (2022) <italic>Front. Oncol.</italic> 12:877380. doi:&#xa0;<object-id>10.3389/fonc.2022.877380</object-id>
</related-article>
<kwd-group>
<kwd>targeted-therapy</kwd>
<kwd>cancer therapeutics resistance</kwd>
<kwd>cross-resistance</kwd>
<kwd>sequential therapeutics</kwd>
<kwd>personalized oncology</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="1"/>
<word-count count="133"/>
</counts>
</article-meta>
</front>
<body>
<p>In the published article, there was an error in affiliations 1, 2, and 4. In these affiliations, &#x201c;Istituto di Ricerca e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy&#x201d; has been changed to &#x201c;IRCCS Regina Elena National Cancer Institute, Rome, Italy&#x201d;.</p>
<p>The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.</p>
<sec id="s1" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
</article>